Axcelis Technologies, Inc. (ACLS) | The Buildout — AI Infrastructure

——Mkt cap — · 52-wk —–— · YTD — · delayed

Updated Aug 12, 2026Q1 FY2026 reviewed

Axcelis Technologies makes ion implantation equipment used to fabricate memory, power, and mature-node chips for AI infrastructure.

Mid-single-digit FY26

Management raised FY2026 from flat to mid-single-digit revenue growth.

CS&I $83M

Aftermarket revenue was roughly 39% of total in Q2.

Book-to-bill ~1x

Bookings $131M; backlog $452M stable.

China 46% of rev

Up from 40% in Q1 and 32% in Q4 2025.

The Buildout Takeaway

The firmed order book underpinned a guide raise and management's explicit 2027 growth expectation. The key tension is whether a memory-led recovery can broaden before China concentration and the pending SAMR approval become the story.

Analyst coverage

13 analysts·10 Buy2 Hold1 Sell

Coverage is thin — only 1 price estimate, so no target is shown

Management guidance

FY2026 revenue: approximately mid-single-digit year-over-year growth · Q3 2026 revenue ~$230M · Q3 gross margin ~43% · Q3 adjusted EBITDA ~$41M · Q3 diluted EPS ~$1.11 · Q4 2026 revenue expected to increase sequentially

Important: The Buildout is a data analytics platform. Content is generated by algorithms and AI agents using public filings, earnings transcripts, and market data. This is not personalized investment advice.

Our View

The Verdict

Axcelis Technologies designs, manufactures, and services ion implantation equipment used in semiconductor chip fabrication. Ion implantation is a core wafer-processing step that accelerates ions into silicon or silicon carbide to alter electrical properties. The company sells high-current, high-energy, and medium-current implanters, plus lifecycle aftermarket support.

Market Cap	—
Revenue (TTM)	$845M
Revenue Growth	−11.8%
EBITDA Margin (TTM)	13.7%

Net Cash	$325M
Earnings Beats	7 of 7
P/E (TTM)	—
EV/EBITDA (TTM)	—

What We Like

Ion implantation accounted for 98.2% of FY2025 revenue per the 10-K, concentrating the business in one core wafer-processing step.
CS&I aftermarket revenue reached $83M in Q2 2026, roughly 39% of total, and grew more than 30% YoY in Q1 2026.
Bookings firmed for three quarters with book-to-bill near 1x; backlog held at $452M.
Purion XEmax completed a 15 MeV evaluation at a leading foundry for power management ICs.
Memory customer base expanded: follow-on orders from a North American memory maker and a multiple high-current system order in Q2 2026.

What We’re Watching

General mature order rates have not yet picked up, even though sales improved sequentially in Q2 2026.
China revenue rose to 46% in Q2 2026; SMIC is on the U.S. Entity List and relies on a 2020 licensing policy.
Non-GAAP gross margin missed guidance two quarters running: 40.7% vs ~41% in Q1, 42.7% vs ~43% in Q2.
Veeco merger still requires SAMR approval in China; close expected H2 2026.

Bottom Line

The thesis is strengthening near term. Management waited until it had two consecutive quarters of firming bookings, then raised full-year 2026 from flat to mid-single-digit growth and added an explicit 2027 growth expectation. The open question is whether the recovery broadens into general mature orders and whether SAMR clears the Veeco merger on the stated H2 2026 timeline.

Next upThe next discrete catalyst is China SAMR approval for the Veeco merger, expected in H2 2026. Q3 2026 results would test whether revenue reaches the guided ~$230 million and whether bookings stay near the 1x book-to-bill range.

Last Quarter — Q1 FY2026

Earnings Beat

Axcelis reported Q2 2026 revenue of $215 million, above the approximately $205 million guided, with non-GAAP gross margin of 42.7%, slightly below the ~43% guide. System revenue was $132 million and CS&I aftermarket revenue was $83 million. Bookings were $131 million and backlog was $452 million; non-GAAP diluted EPS was $1.06, above the ~$0.90 guide.

Metric	Q1 FY2026	Q4 FY2025	Q1 FY2025	YoY
Revenue	$199M	$238M	$193M	+3.3%
Gross margin	40.5%	47.0%	46.1%	-560bps
EBITDA	$12M	$41M	$34M	−63.0%
EPS	$0.30	$1.10	$0.89	−66.5%
Bookings	$131M	$128M	n/a	—
Backlog	$452M	$453M	n/a	—

We continue to anticipate strong year-over-year growth in 2026 with momentum extending into 2027 as customers accelerate cleanroom investments to support growing demand for DRAM and high-bandwidth memory applications driven by AI.— Management, 2026-08-06

Management tone: Management tone shifted from guarded optimism in Q1 2026 to more confidence in Q2 2026. In Q1, management said 'one quarter is not a trend' and held full-year revenue approximately flat; in Q2 it raised full-year 2026 to mid-single-digit growth and said it anticipates another year of revenue growth in 2027, citing two consecutive quarters of firming bookings.

Management Guidance

For Q3 2026, management guided revenue of approximately $230 million, gross margin of approximately 43%, operating expenses of approximately $62 million, adjusted EBITDA of approximately $41 million, a tax rate of approximately 15%, and diluted EPS of approximately $1.11. For Q4, management expects revenue to increase sequentially from Q3, gross margin to improve slightly, and operating expenses to be slightly higher. Full-year 2026 revenue was raised to approximately mid-single-digit year-over-year growth, and management added that it anticipates another year of revenue growth in 2027.

Business Trajectory

Trajectory

Revenue direction turned positive: trailing revenue growth was +3.3% in Q1 FY2026, and Q2 2026 revenue of $215 million led management to raise the full-year outlook. But profitability is compressed—gross margin fell to 40.5% in Q1 FY2026 and non-GAAP gross margin was 42.7% in Q2, with EBITDA margin at 6.2% in Q1. The recovery is being driven by memory and aftermarket, while power and general mature are improving unevenly.

Revenue & Margin Trajectory

Gross margin as reported.

Share Price — 12 Months

52-week range $78–$189.

Share Price — 12 Months

52-week range $78–$189.

The Numbers

The Model

The model projects FY+1 revenue of $850M and EBITDA of $144M (16.9% margin), rising to $1,020M revenue and $214M EBITDA (21.0% margin) in FY+2. Near-term is anchored by the Q3 2026 revenue guide of ~$230M and the ordering stability implied by book-to-bill near 1x; FY+2 assumes new memory cleanroom capacity and power recovery convert into broader order growth.

Revenue & EBITDA Projections

Solid bars are reported actuals; outlined bars are model projections — not company guidance.

Metric	FY2025	Next FY (E)	Following FY (E)
Revenue	$839M	$850M	$1.0B
YoY Growth	—	+1.3%	+20.0%
EBITDA	$137M	$144M	$214M
EBITDA Margin	16.3%	16.9%	21.0%

Projections are the median of 5 independent model runs. The model’s revenue sits 10.2% above analyst consensus.

What Could Go Right — and Wrong

What good looks like

General mature order rates inflect in late 2026, broadening demand beyond memory and power.
NAND follows DRAM, adding a second memory demand vector.
Additional memory customer orders convert to volume across nodes and regions.
Silicon carbide data-center power demand becomes material rather than TBD.
Veeco merger closes in H2 2026 after China SAMR approval.

What could go wrong

China export-licensing policy changes or SMIC restrictions hit a revenue base that was 46% China in Q2 2026.
Memory cleanroom capacity slips, delaying the expected 2027 step-up.
General mature order rates stay soft, leaving the recovery concentrated.
Gross margin misses again on CS&I mix or higher services costs.
Merger termination or prolonged SAMR delay leaves Axcelis standalone with transaction costs incurred.

What’s Next

Looking Ahead

Management's next 12 months rest on three commitments. Q3 2026 revenue is guided to approximately $230 million and Q4 revenue is expected to increase sequentially, with full-year 2026 now expected to grow mid-single digits. Memory is expected to stay lumpy in 2H 2026 and similar to 1H 2026, with new cleanroom capacity supporting 2027 momentum. Management expects the Veeco merger to close in H2 2026 pending SAMR approval.

Catalysts

Q3 2026Q3 2026 results — Tests ~$230M revenue guide and whether bookings stay near ~1x book-to-bill.
H2 2026Veeco SAMR approval — China approval is the remaining regulatory step for the merger to close.
2H 2026Power and SiC revenue inflection — Second-half power expected stronger; first-half SiC bookings exceeded prior two-year average.
Q4 2026Q4 revenue and margin step-up — Management expects sequential revenue growth and slightly improved gross margin.
2027New memory cleanroom capacity — Tool move-ins expected as new fabs open, supporting another year of growth.

Numbers

Financials

Annual Summary

Metric	FY2024	FY2025	TTM	YoY
Revenue	$1.0B	$839M	$845M	-17.6%
Gross Margin	44.7%	44.9%	43.6%	+23bps
EBITDA	$227M	$137M	$1.3B	-39.6%
EBITDA Margin	22.3%	16.3%	13.7%	594bps
Net Income	$201M	$120M	$101M	-40.2%
Free Cash Flow	$129M	$107M	$863M	—
Net Cash	—	—	—	—

Key Ratios (Trailing)

Valuation

P/E TTM—
EV/EBITDA TTM—
EV/Revenue TTM—
Price/FCF TTM—

Profitability

Gross Margin (TTM)43.6%
EBITDA Margin (TTM)13.7%
Net Margin (TTM)11.9%
ROIC10.8%
FCF Conversion76.3%
SBC / Revenue2.4%

Reference

The Company

Axcelis designs, manufactures, and services ion implantation and other processing equipment used in semiconductor chip fabrication. Ion implantation is a core wafer-processing step that accelerates ions into silicon or silicon carbide to alter electrical properties. The company markets high-current, high-energy, and medium-current implanters such as the Purion H6 and Purion XEmax, along with the Ovation batch family and Purion Power Series.

Axcelis operates from leased facilities in Beverly, Massachusetts—a 417,000-square-foot principal facility and a 101,800-square-foot logistics center—plus a 38,000-square-foot Asia Operations Center in South Korea. It reports two segments: Ion Implantation Systems and Aftermarket Support and Services (CS&I). Management says the company has capacity to support higher revenue levels than current levels.

Business Segments

Ion Implantation Systems

$132M system revenue in Q2 2026

Designs, manufactures, and services ion implantation equipment for semiconductor fabs.

Growth driver: Memory DRAM/HBM and power/SiC capacity additions.

Aftermarket Support and Services (CS&I)

$83M in Q2 2026, roughly 39% of total revenue

Used tools, spare parts, equipment upgrades, and maintenance services.

Growth driver: Higher fab utilization drives spares, consumables, and upgrades.

Competitive Landscape

The 10-K names Applied Materials as Axcelis's primary competitor in ion implantation systems. Other named competitors are Sumitomo Heavy Industries Ion Technology and Nissin Ion Equipment in Japan, Advanced Ion Beam Technology in Taiwan, and Kingstone Semiconductor and CETC Electronics Equipment Group in China. The source does not assign market-share labels beyond Applied Materials as the main competitor.

Applied Materials, Inc.
Named as the primary competitor in ion implantation systems.
Sumitomo Heavy Industries Ion Technology Co. Ltd.
Named competitor in Japan.
Nissin Ion Equipment Co., Ltd.
Named competitor in Japan.
Advanced Ion Beam Technology, Inc.
Named competitor in Taiwan.
Kingstone Semiconductor
Named competitor in China.

Six competitors are named in the FY2025 10-K; CETC Electronics Equipment Group is omitted here due to the five-row limit.

Supply Chain

Axcelis sits between component suppliers and semiconductor fabs, selling ion implanters and aftermarket support. The 10-K says it relies on a limited group of outside vendors for components and sub-assemblies. Neighbor read-throughs are external and do not come from Axcelis disclosures.